Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 421 participants.

Also called NCT04198701

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 421 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04198701
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, France, Japan, Netherlands, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04198701. Non-randomized; no masking; primary purpose treatment. Start 2019-12-10 (actual); primary completion 2022-11-28 (actual). Results posted on 2023-12-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
Acronym
PULSED AF
Intervention (Device)
Medtronic PulseSelect Pulsed Field Ablation (PFA) System
Lead sponsor
Medtronic Cardiac Ablation Solutions (class: industry)

Record details

Record id
cardio:ct-nct04198701
Content hash
ac8d1f0e9e7fa35242cb8902e12c0b134c73716c6ca6f31ddd31f0fbed5adbcf